A distinct gut microbiome signature has been identified in people with IBS who are responsive to low FODMAP dietary therapy.
And if confirmed in further studies, the unique gut microbiome subtypes found in IBS may be useful as a biomarker to enable clinicians to select patients who are likely to be suitable or unsuitable for FODMAP therapy, according Australian expert Professor Peter Gibson.
In the study, published in Gut, UK researchers analysed the taxonomic and functional profiles of the stool microbiota from 56 people with IBS, and compared these with control subjects from the same household.